source
- Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCLRetrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.onclive · 2mo ago↗ source
- Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shapeIt seems there’s room for two in the MASH market. When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it wou…Endpoints · 2mo ago↗ source
- STAT+: Trump pivots on kratom derivative 7-OH, floating approval for some formsLast year, the FDA had warned that natural opioids in kratom were being turned into harmful products. Now President Trump says approval should be considered.